156 related articles for article (PubMed ID: 27272044)
1. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.
Naranjo ME; de Andrés F; Delgado A; Cobaleda J; Peñas-Lledó EM; LLerena A
Pharmacogenomics J; 2016 Oct; 16(5):485-90. PubMed ID: 27272044
[TBL] [Abstract][Full Text] [Related]
2. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.
Moya G; Dorado P; Ferreiro V; Naranjo MEG; Peñas-Lledó EM; LLerena A
Pharmacogenomics J; 2017 Jul; 17(4):378-381. PubMed ID: 27068265
[TBL] [Abstract][Full Text] [Related]
3. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
5. Frequencies of
Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
[TBL] [Abstract][Full Text] [Related]
6. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
8. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.
Kirchheiner J; Henckel HB; Meineke I; Roots I; Brockmöller J
J Clin Psychopharmacol; 2004 Dec; 24(6):647-52. PubMed ID: 15538128
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.
Lazalde-Ramos BP; Martínez-Fierro Mde L; Galaviz-Hernández C; Garza-Veloz I; Naranjo ME; Sosa-Macías M; Llerena A
Pharmacogenomics; 2014 Feb; 15(3):339-48. PubMed ID: 24533713
[TBL] [Abstract][Full Text] [Related]
10. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Pharmacogenetics; 1999 Oct; 9(5):657-60. PubMed ID: 10591547
[No Abstract] [Full Text] [Related]
11. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
12. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
13. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
González I; Peñas-Lledó EM; Pérez B; Dorado P; Alvarez M; LLerena A
Pharmacogenomics; 2008 Jul; 9(7):833-40. PubMed ID: 18597648
[TBL] [Abstract][Full Text] [Related]
14. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
[TBL] [Abstract][Full Text] [Related]
15. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.
Peñas-Lledó EM; Dorado P; Agüera Z; Gratacós M; Estivill X; Fernández-Aranda F; Llerena A
Mol Psychiatry; 2011 Jul; 16(7):691-2. PubMed ID: 21321564
[No Abstract] [Full Text] [Related]
16. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
17. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.
Saarikoski ST; Sata F; Husgafvel-Pursiainen K; Rautalahti M; Haukka J; Impivaara O; Järvisalo J; Vainio H; Hirvonen A
Pharmacogenetics; 2000 Feb; 10(1):5-10. PubMed ID: 10739167
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of
P Sarmiento A; Dorado P; Borbón A; de Andrés F; LLerena A;
Pharmacogenomics; 2020 Nov; 21(17):1227-1236. PubMed ID: 33124522
[No Abstract] [Full Text] [Related]
[Next] [New Search]